Skip to main content
. 2016 May 17;7(27):41421–41431. doi: 10.18632/oncotarget.9404

Figure 3. Apigenin inhibits NF-κB in human liver cancer.

Figure 3

(A and B) Dual-luciferase assay results for Bel-7402 and PLC/PRF/5 cells suggest that NF-κB is a target gene of apigenin. Apigenin reduced NF-κB expression in the two cell lines. AP-1, STAT3, and cMyc gene expression were not influenced by apigenin. (C) Apigenin reduced NF-κB protein levels in the two cell lines. (D) Apigenin reduced the nuclear to cytoplasmic protein content ratio in the two cell lines. Each experiment was performed in triplicate. The results are shown as the means of the three experiments, and the error bars represent the standard deviation (*P < 0.05).